" class="no-js "lang="en-US"> Lipella Pharmaceuticals Enters Collaboration with Cook MyoSite
Friday, April 12, 2024

Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite

Lipella Pharmaceuticals, a clinical-stage biotechnology company addressing serious diseases with significant unmet need, has entered into a manufacturing collaboration agreement with Cook MyoSite to facilitate Chemistry, Manufacturing, and Control documentation for Lipella’s drug candidate LP-10 (liposomal tacrolimus), aimed at treating hemorrhagic cystitis. LP-10 has been granted Orphan Drug Designation by the FDA.

Lipella recently released positive topline results from its Phase 2a clinical trial evaluating LP-10 as a drug candidate for hemorrhagic cystitis, a rare and debilitating disease with no FDA-approved treatments currently available. The collaboration with Cook MyoSite, a company with 19 years of Good Manufacturing Practice (“GMP”) manufacturing expertise, is expected to greatly accelerate Lipella’s ability to bring new treatments to patients with unmet needs.

Dr. Michael Chancellor, Chief Medical Officer of Lipella, expressed his enthusiasm about the partnership, stating, “Cook MyoSite’s reputation for quality and safety standards, along with their extensive experience in GMP manufacturing, will be invaluable as we develop our IND application for LP-10. We are confident that this collaboration will expedite our efforts to produce clinical supplies and research products for LP-10, ultimately benefiting patients.”

Dr. Jonathan Kaufman, Chief Executive Officer of Lipella, highlighted the importance of CMC documentation in the regulatory approval process, particularly for products developed via the FDA’s 505(b)(2) pathway, such as LP-10. He emphasized that the collaboration with Cook MyoSite will play a crucial role in advancing the commercial approval of LP-10.

Ryan Pruchnic, Managing Vice President of Cook MyoSite, who is also a member of Lipella’s board of directors, expressed Cook MyoSite’s commitment to supporting Lipella’s investigational products.

“LP-10 is an outstanding drug candidate with immense potential to treat patients in need. We are excited to share our knowledge and expertise in GMP manufacturing and contribute to the advancement of this promising therapeutic,” said Mr. Pruchnic.

With this collaboration, Lipella and Cook MyoSite are poised to make a greater impact in addressing the significant unmet need for effective treatments for hemorrhagic cystitis, and further advance LP-10 towards regulatory approval.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more